UK corporate earnings presented a mixed landscape today, anchored by robust trading updates and major portfolio realignments across several key sectors. Infrastructure and medical businesses led the positive momentum, highlighted by Convatec upgrading its full-year revenue guidance and British Land raising its full-year earnings outlook alongside a 7% increase in half-year underlying profit. Financial performance was further boosted by Experian, which launched a $500m share buyback following strong first-half earnings, and EnQuest, which agreed to sell its UK North Sea business for up to $960m to fund expansion in South East Asia. However, macroeconomic headwinds and tariff uncertainties weighed on select industrial firms, with Mpac Group warning that full-year margins will miss forecasts due to customer order delays, even as GSK secured early US FDA approval for its new lung cancer treatment.
Independent energy producer EnQuest ENQ is selling its UK upstream assets and infrastructure to NEO NEXT+ Energy Upstream UK for up to $960m. Total consideration includes $840m in upfront cash on completion, alongside up to $120m in potential milestone payments. The divestment accelerates EnQuest's transition into a growth-focused operator centered on South East Asia while significantly strengthening its balance sheet.
Recruitment specialist Hays HAS issued a positive trading update, indicating that first-half pre-exceptional operating profit will reach at least £35m, significantly beating consensus expectations. Net fee performance in Germany has improved sequentially driven by its contracting arm, positioning the division to return to modest year-on-year growth in Q2. The group also reiterated progress on its efficiency plan, aiming to deliver £50m in annual structural cost savings in FY27.
Medical technology firm Convatec raised its full-year organic revenue growth expectations to between 6.25% and 7.0%, up from its previous target of 5.5% to 6.5%. The upgrade follows strong trading across the first ten months of the year, led by accelerating second-half growth in its Infusion Care and Continence Care divisions. Excluding InnovaMatrix, year-to-date organic revenue grew 6.6%, reflecting market share gains in core wound care and ostomy segments.
Commercial property developer British Land upgraded its full-year earnings outlook following a strong first-half financial report. Underlying profit rose 7% to £166m, driven by 12% like-for-like net rental growth and tight cost discipline. Reflecting this operational momentum, chief executive Jo McNamara raised FY27 underlying EPS guidance to 31.0p, while the interim dividend was increased by 5% to 12.88p per share.
Global data and analytics leader Experian EXPN delivered strong first-half results, with Benchmark EPS rising 15% and organic revenue growing 7%. The company announced a further $500m share repurchase programme, bringing total calendar year buyback announcements to $2.5bn. For the full year FY27, Experian expects organic revenue growth of 6% to 7% and margin expansion of at least 50 basis points.
Healthcare giant GSK GSK announced that the US FDA has granted accelerated approval for Nelkarmi in adults with pretreated, advanced ALK-positive non-small cell lung cancer. The regulatory decision was secured ahead of the agency's 27 November target date, supported by Phase I/II ALKOVE-1 trial data showing durable patient responses. The decision marks GSK's second new medicine approval in lung cancer this year, strengthening its oncology portfolio.
Infrastructure products provider Hill & Smith HILS acquired the business and assets of Southwest Galvanizing for $77m on a cash- and debt-free basis. Based in Houston, Texas, the family-founded company operates from a well-invested facility servicing industrial and infrastructure end-markets. The transaction expands Hill & Smith's galvanizing business into the fast-growing US southwest, complementing its established operations in the midwest and northeast.
Packaging and automation specialist Mpac Group MPAC issued a profit warning, stating full-year FY26 revenue and operating margins will be below previous expectations. The company cited unpredictable order placement and customer delays caused by challenging macroeconomic conditions and US tariffs. Despite the short-term headwinds, order intake at the end of October rose to £126.0m compared to £101.5m in the prior year period.
Property investor CLS Holdings CLI published a third-quarter trading update, setting full-year 2026 EPRA earnings guidance at 3.6p to 4.6p per share. While operational progress saw leasing activity strengthen in Q3 and October, overall results were squeezed by higher finance costs and unfavorable foreign exchange movements. The group confirmed all 2026 debt refinancings are completed or agreed, and asset disposals remain on track to meet full-year targets.
Animal genetics company Genus GNS reported trading for the four months to October in line with market expectations for FY27 constant-currency adjusted pre-tax profit. Robust performance in its PIC porcine business helped offset challenging market conditions in ABS caused by low global dairy prices. Management noted that adverse movements in Latin American currencies will result in a £3m to £4m currency headwind for the year.
Flow control specialist Rotork ROR reported mid-single digit organic constant currency order intake growth during the four months to 31 October 2026. Strong trading in Chemical, Process & Industrial (CPI) and improving trends in Water & Power offset softer conditions in Oil & Gas linked to Middle East disruptions. The group reaffirmed its overall full-year guidance, expecting further operational and financial progress in 2026.